Table 1 A list of major urinary proteomic studies using mass-spectrometry since 2011

Normal human urinary proteomics

Studies involved cataloging, quantifying and profiling proteins in normal human urine as well as urine protein changes associated with, pregnancy, normal renal function, tobacco smoking and individual variation

LC–MS/MS

HPLC-Chip-MS/MS

[10]

[166]

[170]

[171]

[172]

[173]

[174]

[175]

[176]

[177]

[178]

[57]

[16]

[179]

[180]

[142]

[47]

[181]

[182]

[183]

[184]

[185]

Urine proteomics in cancer

Application of urinary proteomics in identification of non-invasive diagnostic biomarkers for numerous cancer types including bladder cancer, prostate cancer, lung cancer, gastric cancer and cholangiocarcinoma

MALD-TOF

LC–MS/MS

CE-MS

[70]

[186]

[75]

[76]

[187]

[72]

[188]

[73]

[189]

[190]

[191]

[192]

[193]

[194]

[195]

[196]

[197]

[198]

[199]

[200]

[74]

[201]

[151]

[202]

[203]

[204]

[205]

[206]

[207]

[208]

[209]

[66]

[210]

[211]

[212]

[213]

[214]

[215]

[216]

[217]

[218]

[219]

[220]

[221]

[222]

[223]

[224]

[62]

[225]

[226]

Urine proteomics in other pathologies

Pathological conditions such as urinary tract infections, diabetic nephropathy, chronic kidney disease, coronory artery disease, pre-eclampsia, tuberculosis, SARS-CoV-2 and other immunological morbidities have been assessed with the help of urine proteomics

SELDI-TOF

CE-MS

LC–MS/MS

Targeted mass spectrometry

[227]

[228]

[229]

[230]

[231]

[232]

[233]

[234]

[235]

[236]

[237]

[101]

[85]

[238]

[239]

[240]

[241]

[242]

[243]

[244]

[245]

[246]

[247]

[248]

[249]

[250]

[251]

[252]

[253]

[254]

[255]

[99]

[256]

[257]

[258]

[259]

[260]

[105]

[261]

[262]

[263]

[31]

[264]

[265]

[266]

[267]

[268]

[269]

[90]

[6]

[270]

[271]

[91]

[272]

[273]

[274]

[56]

[275]

[276]

[277]

[278]

[87]

[279]

[280]

[281]

[282]

[283]

[284]